|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 230.69 USD | -1.49% |
|
-3.26% | +11.47% |
| 04-20 | Guggenheim Adjusts Price Target on Johnson & Johnson to $266 From $244, Maintains Buy Rating | MT |
| 04-18 | US judge rejects Bayer bid to block Johnson & Johnson prostate cancer drug claims | RE |
Business description: Johnson & Johnson
- pharmaceutical products (64.1%): drugs intended for the treatment of cardiovascular diseases, oncological diseases, gastro-intestinal illnesses, infectious, immunological, neurological, dermatological diseases, etc.;
- medical products and equipment (35.9%): diagnostic systems, orthopedic and gynecological equipment, surgical materials, etc. for use by healthcare professionals;
At the end of 2025, Johnson & Johnson has 63 manufacturing facilities located in the United States (22), North America (7), Europe (22), Africa and Asia/Pacific (12).
The United States accounts for 57.1% of net sales.
Number of employees: 138,200
Sales by Activity: Johnson & Johnson
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
Innovative Medicine | 52.08B | 52.56B | 54.76B | 56.96B | 60.4B |
Medtech | 27.06B | 27.43B | 30.4B | 31.86B | 33.79B |
Consumer Health | 14.64B | 14.95B | - | - | - |
Geographical breakdown of sales: Johnson & Johnson
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
United States | 47.16B | 48.58B | 46.44B | 50.3B | 53.75B |
Europe | 23.59B | 23.45B | 20.41B | 20.21B | 21.54B |
Asia-Pacific, Africa | 17.28B | 16.79B | 13.76B | 13.59B | 14.03B |
Western Hemisphere, Excluding U.S. | 5.75B | 6.12B | 4.55B | 4.71B | 4.88B |
Executive Committee: Johnson & Johnson
| Manager | Title | Age | Since |
|---|---|---|---|
Joaquin Duato
CEO | Chief Executive Officer | 63 | 02/01/2022 |
Joseph Wolk
DFI | Director of Finance/CFO | 59 | 30/06/2018 |
Penny M. Heaton
CTO | Chief Tech/Sci/R&D Officer | 61 | 31/07/2024 |
Kathryn Wengel
CTO | Chief Tech/Sci/R&D Officer | 60 | 31/12/2022 |
James Swanson
CTO | Chief Tech/Sci/R&D Officer | 60 | 04/11/2019 |
Composition of the Board of Directors: Johnson & Johnson
| Director | Title | Age | Since |
|---|---|---|---|
Mark McClellan
BRD | Director/Board Member | 62 | 14/10/2013 |
Mary Beckerle
BRD | Director/Board Member | 71 | 08/06/2015 |
Joaquin Duato
CHM | Chairman | 63 | 01/01/2023 |
Jennifer Doudna
BRD | Director/Board Member | 62 | 12/02/2018 |
Marillyn Hewson
BRD | Director/Board Member | 72 | 24/04/2019 |
Hubert Joly
BRD | Director/Board Member | 66 | 04/12/2019 |
Mark Weinberger
BRD | Director/Board Member | 64 | 04/12/2019 |
Nadja West
BRD | Director/Board Member | 64 | 02/12/2020 |
Paula Johnson
BRD | Director/Board Member | 66 | 13/02/2023 |
Eugene Woods
BRD | Director/Board Member | 61 | 29/11/2023 |
Holdings: Johnson & Johnson
| Name | Equities | % | Valuation |
|---|---|---|---|
IDORSIA LTD 3.8% | 9,581,882 | 3.8% | 41 M $ |
| 219,139 | 2.72% | 777 943 $ |
Company details: Johnson & Johnson
Group companies: Johnson & Johnson
| Name | Category and Sector |
|---|---|
Synthes, Inc. (Pennsylvania)
 Synthes, Inc. (Pennsylvania) Medical/Nursing ServicesHealth Services Provides medical products |
Medical/Nursing Services
|
ABIOMED Europe GmbH
 ABIOMED Europe GmbH Medical SpecialtiesHealth Technology Manufactures and markets micro blood pumps |
Medical Specialties
|
Synthes Holding AG
 Synthes Holding AG MiscellaneousMiscellaneous Functions as an investment holding company |
Miscellaneous
|
Johnson & Johnson de Chile SA
 Johnson & Johnson de Chile SA Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical and health care products |
Pharmaceuticals: Major
|
Johnson & Johnson de México SA de CV
 Johnson & Johnson de México SA de CV Medical DistributorsDistribution Services Distributes healthcare and personal care products |
Medical Distributors
|
Other Pharmaceuticals
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.49% | -3.26% | +46.50% | +41.94% | 564B | |
| -0.77% | -2.08% | +9.52% | +148.31% | 830B | |
| -2.24% | -2.03% | +17.76% | +26.36% | 369B | |
| +2.07% | +1.39% | +25.20% | +16.28% | 328B | |
| -1.10% | -1.83% | +47.69% | +24.68% | 318B | |
| -1.65% | -3.56% | +50.13% | +2.60% | 294B | |
| -0.50% | -2.91% | +30.44% | +33.98% | 291B | |
| -1.45% | -0.25% | +26.28% | +42.22% | 192B | |
| -0.96% | +7.17% | -38.78% | -54.04% | 182B | |
| -1.29% | -2.24% | +29.97% | +61.54% | 171B | |
| Average | -0.48% | +0.13% | +24.47% | +34.39% | 353.84B | |
| Weighted average by Cap. | -0.32% | -0.47% | +25.66% | +53.41% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- JNJ Stock
- Company Johnson & Johnson
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition